Title: Multimodal profiling reveals Mycobacterium tuberculosis restricts lung mitochondrial immunometabolism to promote pathogenesis

This study reveals that *Mycobacterium tuberculosis* promotes pathogenesis by inducing mitochondrial dysfunction and restricting oxidative phosphorylation in the early lung, whereas maintaining robust mitochondrial metabolism is essential for generating protective immune responses.

The Gist

The Big Picture: A Battle for the Lung's Power Plant

Imagine your lungs as a bustling city. When the bacteria that causes Tuberculosis (Mycobacterium tuberculosis, or Mtb) invades, it's like an enemy army trying to take over the city.

The city's defense force (your immune system) has two main ways to fight back:

1. The Sprint: A quick, explosive burst of energy (like running a 100-meter dash). This is called glycolysis. It's fast but doesn't last long and produces a lot of waste.
2. The Marathon: A steady, efficient, long-term energy source (like running a marathon). This is called mitochondrial respiration (OXPHOS). It requires a working "power plant" (the mitochondria) and produces massive amounts of clean energy (ATP) to keep the troops fighting effectively.

The Discovery:
This paper reveals that the TB bacteria is a sneaky saboteur. It doesn't just hide; it actively breaks the city's power plants. By damaging the mitochondria, the bacteria forces the immune cells to rely only on the "Sprint" (glycolysis). This leaves the immune system exhausted, confused, and unable to coordinate a proper attack, allowing the bacteria to win.

However, the researchers found a "super-weapon" in the form of a specific bacterial protein called Hip1. When they removed this protein (using a mutant version of the bacteria), the immune cells kept their power plants intact. They could run the "Marathon," generate massive energy, and successfully organize a defense that protected the host.

---

The Story in Three Acts

Act 1: The Sabotage (What the Bacteria Does)

When the wild-type TB bacteria enters the lung, it releases a tool called Hip1. Think of Hip1 as a "hacker" that sneaks into the immune cells' control room.

• The Attack: Hip1 cuts up a specific protein (GroEL2) that the bacteria uses to talk to the immune system. But more importantly, this action seems to disrupt the immune cells' mitochondria (their batteries/power plants).
• The Result: The immune cells lose their ability to use oxygen to make energy. They are forced to switch to a less efficient fuel source (sugar/glycolysis).
• The Analogy: Imagine a car engine that has had its spark plugs removed. The car can still sputter along on a backup battery (glycolysis), but it can't drive fast or far. The immune cells are "sputtering." They are tired, they can't talk to each other well, and they fail to recruit the "special forces" (T-cells) needed to win the war.

Act 2: The Rescue (What Happens Without Hip1)

The researchers tested a version of the bacteria that lacked the Hip1 tool.

• The Difference: Without the hacker, the immune cells' mitochondria stayed healthy and strong.
• The Result: These cells could run the "Marathon." They produced huge amounts of energy (ATP) by burning fats and amino acids efficiently.
• The Analogy: This is like a fully charged, high-performance electric vehicle. Because they had plenty of energy, the immune cells could:
  1. Talk to each other: They sent clear signals to call in reinforcements.
  2. Coordinate: They successfully linked up with T-cells (the special forces) to launch a precise attack.
  3. Win: The result was a "protective" outcome where the body controlled the infection without destroying its own lung tissue.

Act 3: The Universal Code (Why This Matters for Humans)

The researchers didn't just stop at mice. They looked at data from monkeys and humans.

• The Pattern: They found that in humans who successfully fight off TB (or have latent, non-disease TB), their immune cells show a specific "signature" of healthy mitochondria.
• The Contrast: In people who get sick with active TB, that mitochondrial signature is missing. Their immune cells are stuck in the "sputtering" mode.
• The "Resistors": They even found a group of people called "Resistors"—people who are exposed to TB but never get infected. These people have the strongest mitochondrial signatures of all. It's as if their immune system's power plants are so robust that the bacteria can't break them.

---

The "Aha!" Moment: Why This Changes Everything

For a long time, scientists thought the immune system's switch to "glycolysis" (the sprint) was a good thing—a sign of a strong, angry immune response.

This paper flips that script.
It suggests that while the "sprint" happens, it's actually a sign that the bacteria has broken the power plant. The immune system isn't choosing the sprint because it's strong; it's sprinting because the marathon track is broken.

The Takeaway:
To cure TB or make better vaccines, we shouldn't just try to make the immune system "angrier." Instead, we need to protect the mitochondria.

• Vaccines: We need vaccines that teach the immune cells to keep their power plants running, even when the bacteria tries to sabotage them.
• Medicine: We might be able to develop drugs that fix the mitochondrial damage, giving the immune system the energy it needs to finally win the battle.

Summary Analogy

Think of the immune system as a fire department.

• Healthy State: The fire trucks have full tanks of gas and working engines (Mitochondria/OXPHOS). They can drive to the fire, stay there for hours, and put it out completely.
• TB Infection (Wild Type): The bacteria pours glue in the gas tanks. The fire trucks can only sputter for a few minutes (Glycolysis) before running out of juice. They arrive at the fire, panic, and leave before the fire is out. The building (the lung) burns down.
• The Solution: If we can keep the gas tanks clean (by blocking the bacteria's glue/Hip1), the fire trucks stay strong, coordinate their attack, and save the building.

Technical Summary

1. Problem Statement

Tuberculosis (TB) outcomes range from asymptomatic latent infection to active, destructive disease. While the role of specific immune cells (e.g., macrophages, T cells) is well-studied, the early immunometabolic events in the lung that determine whether an infection leads to protective immunity or pathogenic disease remain poorly understood. Specifically, it is unclear how Mycobacterium tuberculosis (Mtb) manipulates host cellular metabolism to evade immunity. The authors hypothesize that Mtb restricts mitochondrial function in the early lung to limit energy output (ATP), thereby impairing the immune response. They utilize the Mtb hip1 mutant (lacking the serine protease Hip1, a known virulence factor) as a model to contrast pathogenic (Wild Type, WT) vs. protective immune environments, as the hip1 mutant induces robust protective immunity despite similar early bacterial burdens.

2. Methodology

The study employed a multimodal systems biology approach on C57BL/6 mice infected via aerosol with ~100 CFU of either WT Mtb (H37Rv) or the hip1 mutant. Lungs were harvested at 2 weeks post-infection (wpi), a time point where bacterial burdens were equivalent between groups, allowing for the isolation of immune signaling differences from bacterial load differences.

• High-Dimensional Flow Cytometry: Used to profile immune cell frequencies and subsets (macrophages, monocytes, T cells, etc.) in the lung.
• Single-Cell RNA Sequencing (scRNAseq): Performed on ~40,000 lung cells to generate a global cellular map, identify cell subpopulations (e.g., AM1, AM2, AM3, IMs), and analyze differential gene expression (DEG).
• Computational Modeling:
  • Compass: A flux balance analysis tool using scRNAseq data to predict metabolic fluxes and pathways.
  • Gene Co-expression Network (GCN) & LASSO: Used to derive core transcriptional signatures distinguishing WT from hip1 mutant infections.
  • CellChat: Analyzed cell-cell communication networks (ligand-receptor interactions).
• Untargeted Metabolomics: LC-MS analysis of lung homogenates (cellular and extracellular fractions) to quantify metabolites.
• Functional Assays:
  • SCENITH (Single Cell ENergetIc metabolism by profiIing Translation InHibition): Flow cytometry-based assay using puromycin incorporation to assess reliance on glycolysis vs. oxidative phosphorylation (OXPHOS) in single cells.
  • ATP Quantification: Measured intracellular ATP levels in Bone Marrow-Derived Macrophages (BMDMs) treated with Oligomycin.
  • Transmission Electron Microscopy (TEM): Visualized mitochondrial ultrastructure (mass, morphology, circularity).
• Cross-Species Validation: Applied derived gene signatures (MitoCore and LASSO) to public transcriptomic datasets from mice, Non-Human Primates (NHP), and humans (including "Resistors" who remain IGRA-negative despite exposure).

3. Key Contributions

• Identification of a Mitochondrial Immunometabolic Signature: The study defines a specific gene signature (MitoCore and LASSO) enriched in protective immune responses, characterized by upregulated mitochondrial OXPHOS, fatty acid oxidation (FAO), and amino acid oxidation (AAO).
• Mechanistic Role of Hip1: Demonstrates that the Mtb virulence factor Hip1 is a primary driver of mitochondrial dysfunction. In its absence (hip1 mutant), the host maintains mitochondrial integrity and metabolic flexibility.
• Metabolic Rewiring as a Virulence Strategy: Challenges the prevailing view that Mtb simply induces glycolysis; instead, it shows Mtb actively suppresses OXPHOS and mitochondrial mass, forcing immune cells into a low-energy glycolytic state that fails to support effective immunity.
• Translational Relevance: Validates that this mitochondrial signature correlates with protective outcomes (Latent TB, bacterial control) in NHPs and humans, suggesting it is a conserved biomarker for vaccine efficacy and disease resistance.

4. Key Results

A. Transcriptional and Metabolic Divergence

• Gene Expression: scRNAseq revealed that hip1 mutant-infected lungs showed significant upregulation of mitochondrial genes (e.g., mt-Atp6, mt-Nd2, mt-Nd4) and OXPHOS pathways across macrophages, monocytes, and T cells, whereas WT-infected lungs did not.
• Metabolomics: hip1 mutant lungs exhibited higher levels of metabolites associated with FAO, AAO, and TCA cycle completion (e.g., decanoyl-CoA, glutamine, threonine). Conversely, WT lungs showed accumulation of TCA intermediates like itaconate and linoleate, indicating TCA cycle disruption and a shift toward lipid synthesis/glycolysis.
• Compass Analysis: Predicted that hip1 mutant cells had higher flux through ATP-generating pathways (OXPHOS, FAO) compared to WT cells, which were restricted to glycolysis.

B. Macrophage and Monocyte Subsets

• Subpopulation Analysis: Macrophages were clustered into AM1, AM2, AM3, and Interstitial Macrophages (IM).
• Pseudotime Trajectory: In hip1 mutant infections, AM1 cells differentiated into AM2/AM3/IM subsets with high expression of the MitoCore signature. In WT infections, this differentiation occurred without the acquisition of mitochondrial metabolic programs.
• Monocytes: Similar mitochondrial upregulation was observed in monocytic subsets (Mono1, Mono2, Mono3) in the hip1 group.

C. Functional Validation of Mitochondrial Dysfunction

• SCENITH Assay:
  • WT Mtb AMs: Relied heavily on glycolysis (protein synthesis inhibited by 2-DG, not Oligomycin).
  • hip1 Mutant AMs: Relied on OXPHOS (protein synthesis inhibited by Oligomycin, not 2-DG).
• ATP & Morphology:
  • WT-infected macrophages had lower mitochondrial mass and aberrant morphology (smaller area, lower circularity) compared to hip1 mutants.
  • Oligomycin treatment significantly reduced ATP in hip1-infected BMDMs but had no effect on WT-infected BMDMs, confirming WT cells do not use OXPHOS for energy.

D. Impact on Immune Signaling and T Cell Interaction

• Cell-Cell Communication: CellChat analysis showed WT lungs lacked critical MHC-II and CD40-CD40L signaling networks between macrophages and T cells. Instead, WT lungs showed strong eicosanoid signaling (PGE2, LTB4) associated with immunosuppression and inflammation.
• T Cell Responses: hip1 mutant infection led to earlier and stronger Th17 (IL-17+) and Th1 responses. WT infection resulted in delayed T cell recruitment and suboptimal activation.

E. Cross-Species Validation

• The MitoCore module score was significantly higher in:
  • NHPs with Latent TB (LTBI) vs. Active TB (ATB).
  • NHPs with low-burden granulomas (bacterial control) vs. high-burden.
  • Human "Resistors" (IGRA-negative despite exposure) vs. LTBI individuals.
• In mouse models of disease progression, the MitoCore score declined from 2 to 6 weeks, correlating with worsening disease.

5. Significance and Conclusion

This study fundamentally shifts the understanding of Mtb pathogenesis by identifying mitochondrial restriction as a key virulence mechanism.

• Mechanism: Mtb uses the protease Hip1 to cleave host substrates (likely GroEL2), leading to mitochondrial dysfunction, TCA cycle disruption, and a forced reliance on inefficient glycolysis. This results in low ATP output, preventing the energy-intensive processes required for effective antigen presentation and T cell costimulation (specifically CD40 signaling).
• Therapeutic Implications:
  • Vaccines: Strategies that enhance mitochondrial metabolism (OXPHOS, FAO) and CD40 signaling could improve vaccine efficacy by promoting protective Th1/Th17 responses.
  • Host-Directed Therapy (HDT): Targeting mitochondrial pathways or inhibiting Hip1-mediated suppression could restore host energy metabolism, tipping the balance from pathogenic to protective immunity.
• Biomarkers: The identified mitochondrial gene signatures serve as potential biomarkers for predicting disease progression and vaccine efficacy across species.

In summary, the maintenance of intact mitochondrial metabolism in the early lung is pivotal for generating the energy required to mount protective immunity against TB, and Mtb actively subverts this process to ensure its survival and pathogenesis.